Nasal spray vaccine plus immunotherapy shows promise in early throat cancer trial

NCT ID NCT07565740

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether a nasal spray vaccine (WSK-IM05) combined with an immunotherapy drug (tislelizumab) can safely shrink HPV-positive throat tumors before surgery. Nine adults with newly diagnosed, resectable HPV-positive oropharyngeal cancer will receive two cycles of the combination, then undergo surgery followed by standard care. The main goals are to check safety and see how well the tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
WSK-IM05 (nasal spray vaccine) and tislelizumab (immunotherapy drug)
What this could lead to
If it works, this could point toward a less invasive way to treat HPV-positive throat cancer by shrinking tumors before surgery and possibly reducing the need for harsh treatments afterward.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants, so results may not apply broadly. The combination may cause significant side effects, and the vaccine plus immunotherapy might not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.